SuPAR, biomarkers of inflammation, and severe outcomes in patients hospitalized for COVID‐19: The International Study of Inflammation in COVID‐19
Journal of Medical Virology · 2024
DOI: 10.1002/jmv.29389 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of Medical Virology, 2024. Verfasst von Alexi Vasbinder und 33 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA. Hauptthemen laut MEDLINE: Receptors, Urokinase Plasminogen Activator, COVID-19. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIDDK NIH HHS, NHLBI NIH HHS, National Heart, Lung, and Blood Institute.
Abstract (Originalsprache)
Severe coronavirus disease 2019 (COVID‐19) is a hyperinflammatory syndrome. The biomarkers of inflammation best suited to triage patients with COVID‐19 are unknown. We conducted a prospective multicenter observational study of adult patients hospitalized specifically for COVID‐19 from February 1, 2020 to October 19, 2022. Biomarkers measured included soluble urokinase plasminogen activator receptor (suPAR), C‐reactive protein, interleukin‐6, procalcitonin, ferritin, and D‐dimer. In‐hospital outcomes examined include death and the need for mechanical ventilation. Patients admitted in the United States (US, n = 1962) were used to compute area under the curves (AUCs) and identify biomarker cutoffs. The combined European cohorts ( n = 1137) were used to validate the biomarker cutoffs. In the US cohort, 356 patients met the composite outcome of death ( n = 197) or need for mechanical ventilation ( n = 290). SuPAR was the most important predictor of the composite outcome and had the highest AUC (0.712) followed by CRP (0.642), ferritin (0.619), IL‐6 (0.614), D‐dimer (0.606), and lastly procalcitonin (0.596). Inclusion of other biomarkers did not improve discrimination. A suPAR cutoff of 4.0 ng/mL demonstrated a sensitivity of 95.4% (95% CI: 92.4%–98.0%) and negative predictive value (NPV) of 92.5% (95% CI: 87.5%–96.9%) for the composite outcome. Patients with suPAR < 4.0 ng/mL comprised 10.6% of the cohort and had a 0.8% probability of the composite outcome. Applying this cutoff to the validation cohort yielded a sensitivity of 93.8% (90.4%–96.7%) and NPV of 95.5% (93.1%–97.8%) for the composite outcome. Among commonly measured biomarkers, suPAR offered stronger discriminatory ability and may be useful in triaging low‐risk patients with COVID‐19.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cardiology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
- Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
- Department of Biostatistics, School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.
- Department of Clinical Research, Copenhagen University Hospital Amager and Hvidovre, Hvidovre, Denmark.
- Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan, USA.
- Clinic for Gastroenterology, Hepatology and Infectious Diseases, Medical Faculty, University Hospital Düsseldorf, Düsseldorf, Germany.
ORCID-Profile: Athanasios Chalkias
Förderung
- NIDDK NIH HHS
- NHLBI NIH HHS
- National Heart, Lung, and Blood Institute
- National Institute of Diabetes and Digestive and Kidney Diseases
- University of Michigan
Zitieren
APA
Vasbinder, A., Padalia, K., Pizzo, I., Machado, K., Catalan, T., Presswalla, F., Anderson, E., Ismail, A., Hutten, C., Huang, Y., Blakely, P., Azam, T. U., Berlin, H., Feroze, R., Launius, C., Meloche, C., Michaud, E., O'Hayer, P., Pan, M., …, & ISIC investigators (2024). SuPAR, biomarkers of inflammation, and severe outcomes in patients hospitalized for COVID‐19: The International Study of Inflammation in COVID‐19. Journal of Medical Virology. https://doi.org/10.1002/jmv.29389
Vancouver
Vasbinder A, Padalia K, Pizzo I, Machado K, Catalan T, Presswalla F, et al. SuPAR, biomarkers of inflammation, and severe outcomes in patients hospitalized for COVID‐19: The International Study of Inflammation in COVID‐19. Journal of Medical Virology. 2024. doi:10.1002/jmv.29389
BibTeX
@article{Vasbinder2024,
author = {Vasbinder, Alexi and Padalia, Kishan and Pizzo, Ian and Machado, Kristen and Catalan, Tonimarie and Presswalla, Feriel and Anderson, Elizabeth and Ismail, Anis and Hutten, Christina and Huang, Yiyuan and Blakely, Pennelope and Azam, Tariq U and Berlin, Hanna and Feroze, Rafey and Launius, Christopher and Meloche, Chelsea and Michaud, Erinleigh and O'Hayer, Patrick and Pan, Michael and Shadid, Husam R and Rasmussen, Line Jee Hartmann and Roberts, Donald A and Zhao, Lili and Banerjee, Mousumi and Murthy, Venkatesh and Loosen, Sven H and Chalkias, Athanasios and Tacke, Frank and Reiser, Jochen and Giamarellos-Bourboulis, Evangelos J and Eugen-Olsen, Jesper and Pop-Busui, Rodica and Hayek, Salim S and ISIC investigators, ISIC investigators},
title = {SuPAR, biomarkers of inflammation, and severe outcomes in patients hospitalized for COVID‐19: The International Study of Inflammation in COVID‐19},
journal = {Journal of Medical Virology},
year = {2024},
doi = {10.1002/jmv.29389}
}
EUVIMED